Ulcerative Colitis

Biweekly infusions of olamkicept 600 mg increased the likelihood of clinical response and mucosal healing at 12 weeks in patients with active ulcerative colitis compared with placebo, according to results published in JAMA.

Topline findings from the phase 3 INSPIRE induction trial showed that Skyrizi, met the primary endpoint of achieving clinical remission at 12 weeks in adults with moderately to severely active ulcerative colitis, AbbVie announced.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

With recent data highlighting the emotional and social challenges of inflammatory bowel disease, AGA has launched the “My IBD Life” campaign to address the growing need for psychosocial support in patient care.

A computer-aided diagnosis system successfully distinguished disease remission from activity and predicted the risk for subsequent flare among patients with ulcerative colitis, according to results published in Gastroenterology.

In a Healio video exclusive, Maria T. Abreu, MD, outlined long-term data presented at the European Crohn’s and Colitis Congress on the use of Stelara among patients with inflammatory bowel disease.

Travel may no longer be daunting for patients with inflammatory bowel disease, thanks to a “one-stop travel advice” website that offers key resources, support and access to a comprehensive network of IBD specialists worldwide.

In a Healio video exclusive, Remo Panaccione, MD, noted the cumulative benefit of Skyrizi and Rinvoq for the induction and maintenance treatment of patients with inflammatory bowel disease.

In this Healio video exclusive, Parakkal Deepak, MBBS, MS, FACG, highlights several challenges faced by individuals with inflammatory bowel disease in South Asia, including an “inadequate availability” of IBD specialists.

Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the potential to transform treatment paradigms — if it can distinguish itself in an already saturated and competitive market.